SGMT
Sagimet Biosciences Inc. Series A Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$540.33M
P/E Ratio
—
EPS
$-1.58
Beta
3.21
52W High
$11.41
52W Low
$3.08
50-Day MA
$5.56
200-Day MA
$6.81
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing transformative therapies for metabolic diseases, primarily targeting non-alcoholic steatohepatitis (NASH). The firm is progressing its lead therapeutic candidate through various clinical trial phases, utilizing unique mechanisms designed to enhance patient outcomes significantly. With a highly experienced leadership team and a robust intellectual property portfolio, Sagimet is strategically positioned to capitalize on the increasing market demand for effective metabolic disease treatments, making it an attractive investment opportunity for institutional investors seeking exposure in the dynamic biotech sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -38.20% |
| Return on Assets | -25.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.42 |
| Price-to-Book | 4.85 |
| Price-to-Sales (TTM) | 52.50 |
| EV/Revenue | 0.276 |
| EV/EBITDA | -1.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $61.18M |
| Float | $29.98M |
| % Insiders | 6.37% |
| % Institutions | 45.02% |
Historical Volatility
HV 10-Day
181.32%
HV 20-Day
141.85%
HV 30-Day
127.92%
HV 60-Day
105.91%
HV Rank
82.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($26.11 target)
1
Strong Buy8
Buy1
HoldData last updated: 4/29/2026